X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2343) 2343
antiviral agents - therapeutic use (1445) 1445
pegylated interferon (1378) 1378
male (1349) 1349
female (1280) 1280
hepatitis c, chronic - drug therapy (1229) 1229
interferon-alpha - therapeutic use (1209) 1209
ribavirin (1200) 1200
gastroenterology & hepatology (1166) 1166
middle aged (1138) 1138
hepatitis c (1127) 1127
adult (1052) 1052
treatment outcome (1002) 1002
ribavirin - therapeutic use (937) 937
interferon (921) 921
drug therapy, combination (889) 889
hepatitis c virus (874) 874
polyethylene glycols - therapeutic use (821) 821
recombinant proteins (742) 742
genotype (681) 681
hepacivirus - genetics (667) 667
therapy (587) 587
biological response modifiers (573) 573
plus ribavirin (554) 554
aged (548) 548
interferon-alpha - administration & dosage (503) 503
pegylated interferon-alpha-2b (503) 503
antiviral agents - adverse effects (501) 501
virus-infection (482) 482
antiviral agents - administration & dosage (481) 481
sustained virological response (481) 481
hepatitis (475) 475
hepatitis c - drug therapy (459) 459
infectious diseases (451) 451
interferon-alpha - adverse effects (442) 442
recombinant proteins - therapeutic use (436) 436
hepatitis c, chronic - virology (429) 429
virology (429) 429
care and treatment (420) 420
combination therapy (418) 418
health aspects (415) 415
hepacivirus - drug effects (407) 407
peginterferon alpha-2a (398) 398
ribavirin - administration & dosage (398) 398
viral load (389) 389
infection (370) 370
polyethylene glycols - administration & dosage (365) 365
chronic hepatitis c (359) 359
pharmacology & pharmacy (333) 333
pegylated interferon-alpha (325) 325
hcv (310) 310
ribavirin - adverse effects (309) 309
virus diseases (296) 296
chronic hepatitis-c (291) 291
drug therapy (291) 291
analysis (290) 290
rna, viral - blood (289) 289
polyethylene glycols - adverse effects (288) 288
antiviral therapy (277) 277
antiviral agents (266) 266
genetic aspects (261) 261
hepatitis c, chronic - complications (261) 261
liver (253) 253
retrospective studies (251) 251
immunology (235) 235
young adult (232) 232
gastroenterology and hepatology (231) 231
peginterferon (231) 231
risk factors (231) 231
virological response (229) 229
virus (227) 227
time factors (226) 226
interferon-alpha (224) 224
hepatocellular-carcinoma (221) 221
combination (220) 220
cirrhosis (219) 219
initial treatment (219) 219
peginterferon alpha-2b (213) 213
telaprevir (213) 213
interleukins - genetics (211) 211
efficacy (209) 209
hepatitis c, chronic - genetics (207) 207
hiv (204) 204
prospective studies (201) 201
hepatology (199) 199
oncology (199) 199
hepatitis b, chronic - drug therapy (197) 197
polyethylene glycols (195) 195
recurrence (193) 193
research (193) 193
infections (188) 188
digestive system diseases (187) 187
interferon-alpha-2b plus ribavirin (186) 186
treatment-naive patients (183) 183
medicine, general & internal (182) 182
recombinant proteins - administration & dosage (179) 179
medicine & public health (178) 178
hepatitis b (177) 177
hepacivirus - isolation & purification (176) 176
il28b (174) 174
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2929) 2929
French (23) 23
German (19) 19
Spanish (19) 19
Korean (13) 13
Japanese (9) 9
Polish (9) 9
Russian (8) 8
Portuguese (5) 5
Turkish (5) 5
Czech (4) 4
Serbian (4) 4
Hungarian (2) 2
Croatian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of virology, ISSN 1098-5514, 2016, Volume 90, Issue 13, pp. 6001 - 6013
Journal Article
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 05/2012, Volume 37, Issue 6, pp. 1444 - 1454
Journal Article
Seminars in immunopathology, ISSN 1863-2300, 2018, Volume 41, Issue 1, pp. 5 - 19
...REVIEW Perspectives on interferon-alpha in the treatment of polycythemia vera and related myeloproliferative neoplasms: minimal residual disease and cure? Hans... 
Cure | Myeloproliferative neoplasms | Minimal residual disease | Internal Medicine | MPN | Inflammation | Vaccination strategies | MPNs | Combination therapy | DNA-hypomethylator | Pegylated interferon-alpha2 | Ruxolitinib | Biomedicine | Immunology | Statins | MRD | TELOMERASE INHIBITOR IMETELSTAT | IMMUNOLOGY | PATHOLOGY | ESSENTIAL THROMBOCYTHEMIA | CALR EXON-9 MUTATIONS | HEMATOPOIETIC STEM-CELLS | MOLECULAR RESPONSE | BONE-MARROW | ACUTE MYELOID-LEUKEMIA | PEGYLATED INTERFERON | TYROSINE KINASE JAK2 | LONG-TERM TREATMENT | Immunologic Surveillance | Myeloproliferative Disorders - diagnosis | Humans | Interferon-alpha - therapeutic use | Treatment Outcome | Myeloproliferative Disorders - drug therapy | Protein Kinase Inhibitors - adverse effects | Polycythemia Vera - diagnosis | Disease Progression | Interferon-alpha - administration & dosage | Neoplasm, Residual | Protein Kinase Inhibitors - administration & dosage | Inflammation - drug therapy | Protein Kinase Inhibitors - therapeutic use | Myeloproliferative Disorders - etiology | Polycythemia Vera - drug therapy | Interferon-alpha - adverse effects | Inflammation - diagnosis | Mutation | Polycythemia Vera - etiology | Transformation | Toxicity | Leukemia | Vaccination | Clinical trials | Polycythemia vera | α-Interferon | Polycythemia | Bone marrow | Janus kinase | Thrombocytosis | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Tyrosine | Antiinflammatory agents | Myelofibrosis | Myeloid leukemia | Chronic myeloid leukemia | Patients | Interferon | Acute myeloid leukemia | Cancer | Tumors | Review
Journal Article